Dasotraline - CAS 675126-05-3
Catalog number: B0084-169261
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C16H15Cl2N
Molecular Weight:
292.203
COA:
Inquire
Targets:
Others
Description:
Dasotraline hydrochloride is a metabolite of sertraline and a novel inhibitor of dopamine and norepinephrine reuptake that blocks dopamine, norepinephrine, andserotonin transporters (IC50= 4, 6, and 11 nM, respectively).
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-169261 5 mg $349 In stock
Bulk Inquiry
Related CAS:
675126-08-6 (hydrochloride)
Synonyms:
(1R,4S)-trans-Norsertraline; Norsertraline, (1R,4S)-trans-; (1R,4S)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-amine
MSDS:
Inquire
InChIKey:
SRPXSILJHWNFMK-MEDUHNTESA-N
InChI:
InChI=1S/C16H15Cl2N/c17-14-7-5-10(9-15(14)18)11-6-8-16(19)13-4-2-1-3-12(11)13/h1-5,7,9,11,16H,6,8,19H2/t11-,16+/m0/s1
Canonical SMILES:
C1CC(C2=CC=CC=C2C1C3=CC(=C(C=C3)Cl)Cl)N
1.Pharmacokinetics and Exposure-Response Relationships of Dasotraline in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults.
Hopkins SC;Sunkaraneni S;Skende E;Hing J;Passarell JA;Loebel A;Koblan KS Clin Drug Investig. 2016 Feb;36(2):137-46. doi: 10.1007/s40261-015-0358-7.
BACKGROUND AND OBJECTIVES: ;Dasotraline is a novel inhibitor of dopamine and norepinephrine reuptake currently being investigated in clinical studies for the treatment of attention-deficit/hyperactivity disorder (ADHD). Uniquely, relative to current ADHD medications, dasotraline has a slow absorption and long elimination half-life. Here we relate the pharmacokinetics and pharmacodynamics of dasotraline to reduction in ADHD symptoms based on simulated clinical trial outcomes.;METHODS: ;Dasotraline pharmacokinetics were analyzed by population pharmacokinetic methodologies using data collected from 395 subjects after single or multiple oral dose administrations ranging from 0.2 to 36 mg (three phase I studies and one phase II ADHD study). Population pharmacokinetic and pharmacodynamic models related individual dasotraline exposures to norepinephrine metabolite 3,4-dihydroxyphenylglycol (DHPG) concentrations, ADHD symptoms, and study discontinuation (probability of dropout).;RESULTS: ;Dasotraline pharmacokinetics were described by a one-compartment model with dual (linear plus nonlinear) elimination. In an ADHD population treated with dasotraline 4 or 8 mg/day, dasotraline was characterized by a mean apparent half-life of 47 h and plasma concentrations reached steady-state by 10 days of dosing.
2.Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults.
Koblan KS;Hopkins SC;Sarma K;Jin F;Goldman R;Kollins SH;Loebel A Neuropsychopharmacology. 2015 Nov;40(12):2745-52. doi: 10.1038/npp.2015.124. Epub 2015 May 7.
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by symptoms of inattention, hyperactivity, and impulsivity associated with clinically significant impairment in functioning. ADHD has an early onset, but frequently persists, with a prevalence estimate of 4% in adults. Dasotraline is a novel compound that is a potent inhibitor of dopamine and norepinephrine transporters that achieves stable plasma concentrations with once-daily dosing. In this study, adult outpatients meeting DSM-IV-TR criteria for ADHD were randomized to 4 weeks of double-blind, once-daily treatment with dasotraline 4 and 8 mg/day or placebo. The primary efficacy end point was change from baseline at week 4 in the ADHD Rating Scale, Version IV (ADHD RS-IV) total score. Secondary efficacy end points included the Clinical Global Impression, Severity (CGI-S) scale, modified for ADHD symptoms. Least squares (LS) mean improvements at week 4 in ADHD RS-IV total score were significantly greater for dasotraline 8 mg/day vs placebo (-13.9 vs -9.7; P=0.019), and nonsignificantly greater for 4 mg/day (-12.4; P=0.076). The LS mean improvements in modified CGI-S were significantly greater at week 4 for dasotraline 8 mg/day vs placebo (-1.
3.SEP-225289 serotonin and dopamine transporter occupancy: a PET study.
DeLorenzo C;Lichenstein S;Schaefer K;Dunn J;Marshall R;Organisak L;Kharidia J;Robertson B;Mann JJ;Parsey RV J Nucl Med. 2011 Jul;52(7):1150-5. doi: 10.2967/jnumed.110.084525. Epub 2011 Jun 16.
SEP-225289 is a novel compound that, based on in vitro potencies for transporter function, potentially inhibits reuptake at dopamine, norepinephrine, and serotonin transporters. An open-label PET study was conducted during the development of SEP-225289 to investigate its dopamine and serotonin transporter occupancy.;METHODS: ;Different single doses of SEP-225289 were administered to healthy volunteers in 3 cohorts: 8 mg (n = 7), 12 mg (n = 5), and 16 mg (n = 7). PET was performed before and approximately 24 h after oral administration of SEP-225289, to assess occupancy at trough levels. Dopamine and serotonin transporter occupancies were estimated from PET using (11)C-N-(3-iodoprop-2E-enyl)-2β-carbomethoxy-3β-(4-methylphenyl)nortropane ((11)C-PE2I) and (11)C-N,N-dimethyl-2-(2-amino-4-cyanophenylthio)benzylamine ((11)C-DASB), respectively. Plasma concentration of SEP-225289 was assessed before ligand injection, and subjects were monitored for adverse events.;RESULTS: ;Average dopamine and serotonin transporter occupancies increased with increasing doses of SEP-225289. Mean dopamine and serotonin transporter occupancies were 33% ± 11% and 2% ± 13%, respectively, for 8 mg; 44% ± 4% and 9% ± 10%, respectively, for 12 mg; and 49% ± 7% and 14% ± 15%, respectively, for 16 mg.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Products


UNIL-088
(CAS: 473545-11-8)

UNIL088 is a water-soluble prodrug of cyclosporine A (CsA), can be rapidly hydrolysed under physiological conditions, and can retain a long shelf-life in aqueou...

CAS 75921-69-6 Melanotan I

Melanotan I
(CAS: 75921-69-6)

A synthetic analogue of α-melanocyte stimulating hormone (α-MSH)

CAS 144092-28-4 Xenin

Xenin
(CAS: 144092-28-4)

Xenin, a 25-amino acid peptide initially isolated from human gastric mucosa, has 6 C-terminal amino acids in common with amphibian xenopsin. Xenin may stimulate...

CAS 39011-90-0 Albiflorin

Albiflorin
(CAS: 39011-90-0)

Albiflorin is a major constituent presents in peony root, which possesses therapeutic potential for neurodegenerative diseases.

CAS 87626-56-0 LM985

LM985
(CAS: 87626-56-0)

LM985, the diethylaminoester derivative of LM975, has anti-tumor activities.

CAS 60-70-8 Veratramine

Veratramine
(CAS: 60-70-8)

Veratramine is useful as a signal transduction inhibitor for treating tumors.

CAS 163133-43-5 4-(NITROOXY)BUTYL (2S)-2-(6-METHOXY-2-NAPHTHYL)PROPANOATE

4-(NITROOXY)BUTYL (2S)-2-(6-METHOXY-2-NA
(CAS: 163133-43-5)

Naproxcinod, a nitro compound, has been found to be a nitric oxide donor as well as a cyclooxygenase inhibitor that was once studied aginast duchenne muscular d...

PF-06471553
(CAS: 1808094-07-6)

PF-06471553, isoindoline-5-sulfonamide, selectively inhibits MGAT3 with high in vitro potency and cell efficacy which displayed suitable PK properties in mouse ...

Chemical Structure

CAS 675126-05-3 Dasotraline

Quick Inquiry

Verification code

Featured Items